EP Patent

EP1891953A1 — Immune response modifier sterile formulations and methods

Assigned to Meda AB · Expires 2008-02-27 · 18y expired

What this patent protects

A pharmaceutical composition comprising an active substance selected from the group consisting of imiquimod (1-(2-methylpropyl)-1 H -imidazo[4,5- c ]quinolin-4-amine), sotirimod(2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine) and resiquimod (4-amino-α,α-di…

USPTO Abstract

A pharmaceutical composition comprising an active substance selected from the group consisting of imiquimod (1-(2-methylpropyl)-1 H -imidazo[4,5- c ]quinolin-4-amine), sotirimod(2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine) and resiquimod (4-amino-α,α-dimethyl-2-ethoxymethyl-1H-imidazo[4,5-c]quinoline-1-ethanol), that is stable to sterilization and suitable for topical application directly to tissue sites where the dermis has been breached, and has been sterilized, packaged compositions that have been sterilized, and methods of sterilizing these compositions are disclosed.

Drugs covered by this patent

Patent Metadata

Patent number
EP1891953A1
Jurisdiction
EP
Classification
—
Expires
2008-02-27
Drug substance claim
No
Drug product claim
No
Assignee
Meda AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.